New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
16:18 EDTPFE, PBYIPuma Biotech now responsible for R&D expenses associated with legacy trials
Puma Biotechnology (PBYI) announced an amendment to its licensing agreement with Pfizer (PFE) for Puma's investigational drug PB272, or neratinib. The amendment to the license agreement provides that Puma will now be solely responsible for the expenses associated with the ongoing legacy clinical trials. Puma anticipates that this will result in an increase in research and development, or R&D, expenses, which will total approximately $30M. Puma further anticipates that a significant percentage of this approximately $30M will occur in FY14 and will decrease over time until the trials are completed. In addition, according to the terms of the original license agreement, upon commercialization of neratinib, Puma is obligated to pay Pfizer incremental annual royalties ranging between 10%-20% of net sales of neratinib. Under the terms of the amendment to the license agreement, upon commercialization of neratinib, Puma will be obligated to pay Pfizer annual royalties on net sales of neratinib at a fixed rate in the low- to mid- teens.
News For PBYI;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
16:08 EDTPFETeva volatility elevated, Pfizer approached late last year, Bloomberg says
Teva (TEVA) overall option implied volatility of 25 compares to its 26-week average of 23 according to Track Data, suggesting large price movement into Pfizer (PFE) approach late last year, Bloomberg says.
16:04 EDTPFETeva rebuffed Pfizer approach late last year, Bloomberg says
Subscribe for More Information
10:02 EDTPBYIOn the Fly: Analyst Initiation Summary
Subscribe for More Information
January 22, 2015
16:16 EDTPBYIPuma Biotechnology initiated with an Outperform at RBC Capital
Subscribe for More Information
11:23 EDTPFEPfizer says CHMP adopted positive opinion on Prevenar 13 expansion
Subscribe for More Information
07:36 EDTPBYIPuma Biotechnology a 'unique takeout candidate,' says Citigroup
Subscribe for More Information
January 21, 2015
19:13 EDTPBYIPuma Biotechnology 1M share Secondary priced at $190.00
Subscribe for More Information
12:30 EDTPFEGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
January 20, 2015
16:25 EDTPBYIPuma Biotechnology files to sell 1M shares of common stock
Subscribe for More Information
16:07 EDTPBYIPuma Biotechnology files automatic mixed securities shelf
Subscribe for More Information
January 15, 2015
11:20 EDTPFEGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
07:59 EDTPFEAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
January 12, 2015
12:45 EDTPFEActavis CEO says 'can't speculate on what Pfizer is going to do'
Subscribe for More Information
09:22 EDTPFE23andMe announces collaboration with Pfizer
Google (GOOG)-backed 23andMe announced an agreement with Pfizer (PFE) that will provide Pfizer with access to 23andMe’s research platform, including services and Research Portal analysis of 23andMe’s genotyped population of over 800,000 individuals, of which more than 80 percent have consented to participate in research. 23andMe’s Research Portal enables qualified and approved scientists outside of 23andMe the opportunity to leverage the company’s unique research model while still protecting the privacy and security of 23andMe’s customers. As a part of the agreement, the companies will collaborate on certain genome-wide association studies, surveys, and clinical trial recruitment. One of these collaborations will be a longitudinal study to better understand the genetics of lupus. This study will entail enrollment and genotyping of 5,000 people into a new lupus research community, and include the integration of medical records, targeted bio-sampling along with genetic information for all participants. This announcement follows a collaboration between 23andMe and Pfizer to enroll 10,000 people with Inflammatory Bowel Disease in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD. Nearly 4,000 patients have been enrolled in the community since August 2014.
08:37 EDTPFEShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use